These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 37415827)

  • 21. Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies.
    Tiwari D; Martineau AR
    Semin Immunol; 2023 Jan; 65():101672. PubMed ID: 36469987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Burden of Chronic Obstructive Pulmonary Disease Attributable to Tuberculosis: A Microsimulation Study.
    Sy KTL; Horváth-Puhó E; Sørensen HT; Szépligeti SK; Heeren TC; Thomsen RW; Fox MP; Horsburgh CR
    Am J Epidemiol; 2023 Jun; 192(6):908-915. PubMed ID: 36813297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary Tuberculosis and the Incidence of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease.
    Park HY; Kang D; Shin SH; Choi H; Jang SH; Lee CH; Kim H; Kwon OJ; Rhee CK; Cho J
    Ann Am Thorac Soc; 2022 Apr; 19(4):640-648. PubMed ID: 34478360
    [No Abstract]   [Full Text] [Related]  

  • 24. Is pulmonary tuberculosis a true risk-factor for chronic obstructive pulmonary disease?
    Jindal SK
    Indian J Tuberc; 2022 Apr; 69(2):131-133. PubMed ID: 35379391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Pathogenesis of Tuberculosis: The Early Infiltrate of Post-primary (Adult Pulmonary) Tuberculosis: A Distinct Disease Entity.
    Hunter RL
    Front Immunol; 2018; 9():2108. PubMed ID: 30283448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding delayed T-cell priming, lung recruitment, and airway luminal T-cell responses in host defense against pulmonary tuberculosis.
    Shaler CR; Horvath C; Lai R; Xing Z
    Clin Dev Immunol; 2012; 2012():628293. PubMed ID: 22545059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutrophils in tuberculosis--first line of defence or booster of disease and targets for host-directed therapy?
    Dallenga T; Schaible UE
    Pathog Dis; 2016 Apr; 74(3):. PubMed ID: 26903072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tuberculosis and lung damage: from epidemiology to pathophysiology.
    Ravimohan S; Kornfeld H; Weissman D; Bisson GP
    Eur Respir Rev; 2018 Mar; 27(147):. PubMed ID: 29491034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infection of
    Le Y; Cao W; Zhou L; Fan X; Liu Q; Liu F; Gai X; Chang C; Xiong J; Rao Y; Li A; Xu W; Liu B; Wang T; Wang B; Sun Y
    Front Immunol; 2020; 11():1902. PubMed ID: 32973788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of covid-19 among patients with chronic obstructive pulmonary disease and tuberculosis.
    Muneeb Hassan M; Ameeq M; Jamal F; Tahir MH; Mendy JT
    Ann Med; 2023 Dec; 55(1):285-291. PubMed ID: 36594409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tuberculosis associated chronic obstructive pulmonary disease.
    Sarkar M; Srinivasa ; Madabhavi I; Kumar K
    Clin Respir J; 2017 May; 11(3):285-295. PubMed ID: 28268242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is Mycobacterium tuberculosis carcinogenic to humans?
    Roy D; Ehtesham NZ; Hasnain SE
    FASEB J; 2021 Sep; 35(9):e21853. PubMed ID: 34416038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unsuspected tuberculosis in COPD and use of levofloxacin: diagnostic challenges.
    Modesto dos Santos V; Martins RR; Fachinelli LR; Araujo MC; dos Santos UM; Ribeiro KD
    Infez Med; 2014 Dec; 22(4):309-12. PubMed ID: 25551847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against
    Chen Y; Xiao JN; Li Y; Xiao YJ; Xiong YQ; Liu Y; Wang SJ; Ji P; Zhao GP; Shen H; Lu SH; Fan XY; Wang Y
    Front Immunol; 2018; 9():3190. PubMed ID: 30700988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disparate Tuberculosis Disease Development in Macaque Species Is Associated With Innate Immunity.
    Dijkman K; Vervenne RAW; Sombroek CC; Boot C; Hofman SO; van Meijgaarden KE; Ottenhoff THM; Kocken CHM; Haanstra KG; Vierboom MPM; Verreck FAW
    Front Immunol; 2019; 10():2479. PubMed ID: 31736945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic airflow obstruction syndrome due to pulmonary tuberculosis treated with directly observed therapy--a serious changes in lung function.
    Radovic M; Ristic L; Stankovic I; Pejcic T; Rancic M; Ciric Z; Dinic-Radovic V
    Med Arh; 2011; 65(5):265-9. PubMed ID: 22073848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinguishing tuberculosis from nontuberculous mycobacteria lung disease, Oregon, USA.
    Kendall BA; Varley CD; Choi D; Cassidy PM; Hedberg K; Ware MA; Winthrop KL
    Emerg Infect Dis; 2011 Mar; 17(3):506-9. PubMed ID: 21392445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with bronchiectasis in patients with moderate-severe chronic obstructive pulmonary disease.
    Jin J; Yu W; Li S; Lu L; Liu X; Sun Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4219. PubMed ID: 27442646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus.
    Behar SM; Carpenter SM; Booty MG; Barber DL; Jayaraman P
    Semin Immunol; 2014 Dec; 26(6):559-77. PubMed ID: 25311810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.